Research conducted by our team is focused on bringing more light into understanding the process of drug resistance with the focus on hematological malignancies, mainly acute myeloid leukemia (AML).
Using cellular and patient-derived models alongside techniques such as flow cytometry, cell sorting, transcriptomics, qRT-PCR and digital PCR, we aim to identify the mechanisms responsible for the development of resistant subsets of AML cells and persistence of minimal residual disease. We further aim to explore the transport of essential molecules (e.g. L-carnitine, cytokines) in pathological, inflammatory and pre-malignant tissue models. Moreover, we employ cell viability and apoptosis assays and cell function-related approaches to address our scientific questions.